Teva Pharmaceuticals

#𝗧𝗲𝘃𝗮𝗧𝗵𝗲𝗻𝗔𝗻𝗱𝗡𝗼𝘄: 𝗣𝗶𝘃𝗼𝘁𝗶𝗻𝗴 𝘁𝗼 𝗚𝗿𝗼𝘄𝘁𝗵 Back in 1901, Chaim Salomon, Moshe Levin and Yitschak Elstein opened a small neighborhood pharmacy. Over 120 years later, the unwavering dedication, purpose, and determination remain as strong as ever: We are all in for better health. With seven consecutive quarters of growth under our belt, Teva’s bold Pivot to Growth strategy drives our focus on innovation, fueled by a robust pipeline of new medicines. With a clear direction and a united leadership, we push boundaries and set higher standards in service of our patients, customers, and healthcare systems. Discover the 4 key initiatives behind Teva’s growth strategy: https://ow.ly/JK5S50UxRgF #Tevapharm

#𝗧𝗲𝘃𝗮𝗧𝗵𝗲𝗻𝗔𝗻𝗱𝗡𝗼𝘄: 𝗘𝗺𝗯𝗿𝗮𝗰𝗶𝗻𝗴 𝗗𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 Since the very beginning, Teva took pride in its people and culture, embracing the creativity that comes with different perspectives and dialogue. In today’s rapidly evolving landscape of medicine development, diversity has become a key driver of innovation. Earlier this year, we sat down with three inspiring leaders from Teva R&D – Heather De Luca, Head of Global Program Leadership; Eric A. Hughes, MD, PhD, Head of Global R&D and Chief Medical Officer; and Sophie Lamle, SVP, Head of Innovative Medicines – to discuss the importance of diversity, innovation, and everything in between. Read the full story here: https://ow.ly/G1UV50UygVK #Tevapharm #ClinicalDevelopment #HealthcareInnovation

#𝗧𝗲𝘃𝗮𝗧𝗵𝗲𝗻𝗔𝗻𝗱𝗡𝗼𝘄: 𝗧𝗲𝗹𝗹𝗶𝗻𝗴 𝗼𝘂𝗿 𝘀𝘁𝗼𝗿𝘆, 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 It all began in 1901, when a modest neighborhood pharmacy opened its doors with a simple yet deeply meaningful mission: To care for the local community by providing essential medicines. Fast forward to today, Teva has grown into a global leader in healthcare. We are stepping up our innovative medicines portfolio and pipeline, while also leading the industry in our commitment to generics and biosimilars. From that small pharmacy to our worldwide impact, our journey is a reflection of the power of dedication, innovation, and staying true to our roots. Celebrating over a century of making a difference. 2025, we’re ready for you! #Tevapharm #HealthcareInnovation #InnovativeMedicines

This time last year, I quietly made a New Year’s resolution. I didn’t post about it, talk about it, or write it down. But, the New Year's resolution I've clearly committed to was this: Making a real impact on people’s lives in 2024. Now, as the year draws to a close, I’m reflecting on the past 12 months with a profound sense of awe at what we’ve achieved. While there will be plenty of opportunity to dive into the numbers and business milestones for the year during our Q4 earnings, I want to take a moment now to focus on what truly matters: the people whose lives we’ve touched with our work. First and foremost, the #patients. They are at the heart of everything we do. Knowing our medicines have helped people - whether it’s managing something as common as a cold or regaining quality of life while living with a chronic illness - is immensely rewarding. I think about the kids out there unwrapping skateboards and footballs this holiday season, not worrying about their next asthma attack. Or the individuals celebrating the New Year with renewed peace of mind, having gained control over #mental health challenges. These moments remind us why we do what we do. Then, there are the #communities we serve. Across nearly 60 countries, our generics and biosimilars have delivered enormous health savings, providing high-quality alternatives that ease the financial burden on healthcare systems. But it doesn’t stop there. In 2024, we expanded our efforts to reach underserved populations, launching our 8th access program. Through this initiative, we’re donating medicines for cardiovascular diseases, diabetes, respiratory illnesses, pain, and palliative care, helping patients living in poverty who otherwise might not have access to basic healthcare. I’m also so proud of my #colleagues. What they have achieved in 2024 is truly remarkable. People should never underestimate the people at Teva. Despite the challenges (and there have been many) we achieved so much this year. Together, this amazing team delivered on our #PivottoGrowth strategy with great numbers, great data and great launches. Lastly, we’re acting now to impact the planet our kids get to live in. Through our #HealthyFuture strategy, we’re embedding sustainable practices into every aspect of our work. From reducing our environmental footprint to promoting access and equity, we’re creating a healthier world for future generations. Whether it’s the millions of patients we are reaching, the ~37,000 employees driving innovation worldwide, or the millions of people in 60 countries benefiting from more accessible healthcare, I believe it’s clear: the people at Teva have made an incredible impact and truly are all in for better health. As we step into 2025, we wish you and your loved ones a healthy, happy, and impactful New Year! Learn more about our impact and purpose here: https://ow.ly/MnQ650U4gv5 #TevaPharm #Innovation #PivottoGrowth #weareallinforbetterhealth

#𝗧𝗲𝘃𝗮𝗧𝗵𝗲𝗻𝗔𝗻𝗱𝗡𝗼𝘄: 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 For over 120 years, our dedicated scientists have been committed to innovation in drug development to address the pressing needs of patients. Today, Teva’s Antibody Discovery team, located in Sydney, Australia, is progressing therapeutic antibody candidates that are manufacturable, safe, and effective into clinical development and finally into the clinic. With recent launches and an extensive pipeline, Teva has acquired industry-leading experience in screening and selecting disease-fighting antibodies for effective therapies. Discover more about Teva’s innovative work in this space: https://ow.ly/fwG550UxR8U #Tevapharm #HealthcareInnovation

🌏 Regardless of where you live, the health of our planet directly affects your health. Clean air and water and a stable climate are essential for preventing disease and promoting overall well-being. That’s why, as a company that strives to improve human health, we’re also committed to safeguarding our environment. Take a look at some of the milestones we've reached as we work towards our goal. 👇 And that’s not all – our progress is being recognized. Recently, TIME named us one of the World’s Most Sustainable Companies for our efforts to protect the planet. Read the full story here: https://ow.ly/3va650TPfYF #EnvironmentalSustainability #ClimateAction #HealthyFuture #TevaPharm #Sustainability

Coping with chronic illness over #Christmas may seem easier said than done. After all, the festive season can be such a stressful time of year for anybody. Add living with a chronic illness like multiple sclerosis (MS) into the mix, and you can quickly feel overwhelmed. Birgit Bauer, a Life Effects contributor, shares her 9 tips for a stress-free Christmas: https://ow.ly/Ye1O50UvUyz #Tevapharm #ChronicIllness

No matter where you are in the world, this season is about sharing special moments with those who matter most. As we look ahead to 2025, we’re inspired to continue making a difference together. Wishing you and your loved ones a joyful holiday season filled with warmth, happiness, and good health. #Tevapharm #SeasonsGreetings

Christmas has been relentlessly marketed as “The most wonderful time of the year.” But, for people with social anxiety, all the expectations and commitments can lead to burnout. Claire Eastham struggled with holiday anxiety, pushing through her discomfort to fit in. This year, she refuses to punish herself for not being an extrovert. Instead, she’s choosing to use self-kindness and care to ensure a happy, reduced-stress Christmas. Read her 6 “Christmas Survival” tips here: https://ow.ly/hewj50Utj2Q #MentalWellness #HolidaySelfCare #SocialAnxiety #Tevapharm

Today, Teva and Sanofi announced positive topline results from our Phase 2b anti-TL1A study investigating a potentially best-in-class treatment option for moderate-to-severe inflammatory bowel diseases (IBD), in patients with ulcerative colitis (UC) and Crohn’s disease (CD). Our commitment to better health for patients is what drives our innovative medicines portfolio, and with approximately 4.9 million cases globally, those living with #IBD are in need of new treatment options. Read more about our anti-TL1A program, and what’s coming next: https://ow.ly/JBWC50UsvYw #TevaPharm #PivotToGrowth #Innovation #UlcerativeColitis #CrohnsDisease